An abstract from the American Heart Association's Scientific Sessions 2026 reveals the continuous expansion of the GLP-1 medication class.
|Slideshows|October 15, 2019
- Drug Topics October 2019
- Volume 163
- Issue 10
5 New Diabetes Technologies and Treatments
Author(s)Drew Boxler
Noteworthy diabetes management products and updates making waves this year.
Advertisement
Like other areas of healthcare, diabetes management in 2019 has been experiencing a combination of new device developments and improvements, technological advancements, new drug approvals, and new partnerships offering a glimpse of distant future possibilities. Here are five noteworthy products and updates that are making waves in the diabetes management space this year:
Articles in this issue
about 7 years ago
The Truth About Statinsabout 7 years ago
Opinion: Color Coded Inhalersabout 7 years ago
Pharmacist Collaborations Must Extend to Dentistsabout 7 years ago
Contemplating the Future of List Pricesabout 7 years ago
New Drug Review: Tafamidis Meglumine for Cardiomyopathyabout 7 years ago
Life-Altering Gene Therapy Pipeline Poses Challengesabout 7 years ago
Solving the Drug Shortage Burdenabout 7 years ago
Providing Healthcare to Transgender Patientsabout 7 years ago
State Laws May Determine Access to Pharmacy-based PrEP Clinicsabout 7 years ago
Official CVS/Aetna Merger: Greater Convenience, Less Cost ReformAdvertisement
Related to this article
Type 1 and type 2 diabetes reports emphasize areas where pharmacists can act now, including CGM, cardio-kidney therapies, and equitable patient access.
Data assessing Novo Nordisk’s investigational diabetes and obesity medication were presented at The Menopause Society's 2026 Annual Meeting.
Eli Lilly released phase 2b trial results comparing the investigational eloralintide-tirzepatide combo with tirzepatide 15 mg alone in patients with T2D and obesity.
At the center of the debate are the growing number of manufacturer demands for claims data as a condition of 340B pricing.
Nicholas Rebold, PharmD, MPH, BCIDP, AAHIVP, discusses his team’s and patients’ experiences in a pharmacist-led antiretroviral initiative.
Zaid Fadul, MD, FS, FAAFP, introduces the Nolla Derm app, what it might mean for pharmacists and their patients, and where AI prescribing is headed in the future.
Among a collection of patients across 15 pharmacies, researchers assessed acceptability and satisfaction with pharmacist-led clinical services.
Advertisement
Advertisement